SEC Form 4 · accession 0001632388-15-000006
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Graeme Wald
Director
Period of report
Feb 10, 2015
Accepted (ET)
Feb 10, 2015 · 2:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 10, 2015 | C | 6,176 | — | A | 6,176 | I | By Wald Funds Pty Ltd <Wald Funds Unit A/C> |
| Ordinary SharesF1,F2 | Feb 10, 2015 | C | 7,548 | — | A | 7,548 | I | By JanCutz Pty Ltd <Emuna Superannuation Fund A/C> |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preference SharesF1,F2 | — | Feb 10, 2015 | C | 6,176 | D | — | — | Ordinary Shares | 6,176 | 0 | I |
| Series B Preference SharesF1,F2 | — | Feb 10, 2015 | C | 7,548 | D | — | — | Ordinary Shares | 7,548 | 0 | I |
Explanation of responses
- F1Reflects automatic conversion of Series B Preference Shares into ordinary shares on a one-for-one basis upon the completion of the initial public offering of Issuer's ordinary shares.
- F2The reporting person has sole voting and dispositive power with respect to these reported securities. The reporting person disclaims beneficial ownership of these reported securities except to the extent of his pecuniary interest therein.